Denosumab (Drug Plan Submission)

Details

Files
Generic Name:
Denosumab (Drug Plan Submission)
Project Status:
Complete
Therapeutic Area:
Prevention of skeletal-related events due to bone metastases from other solid tumors (excluding breast and prostate cancer), including non-small cell lung cancer
Manufacturer:
Amgen Canada Inc.
Call for patient/clinician input open:
Brand Name:
Xgeva
Project Line:
Reimbursement Review
Project Number:
SR0433-001
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Submission Type:
Drug Plan Initiated
Indications:
Prevention of skeletal-related events due to bone metastases from other solid tumors (excluding breast and prostate cancer), including non-small cell lung cancer
Recommendation Type:
List with clinical criteria and/or conditions
Final Recommendation: